SITC 2016 Fellowship Awards

SITC-AstraZeneca Cancer Immunotherapy Clinical Fellowship in Non-Small Cell Lung Cancer (NSCLC) Recipient

Miguel F. Sanmamed, MD, PhD
Yale University, United States
Amount: $100,000 for one year
Project: “Identifying primary and acquired resistance mechanisms to PD-1/PD-L1 pathway blockade in non-small cell lung cancer patients using immune-patient-derived xenograft model”

SITC-Genentech Cancer Immunotherapy Clinical Fellowship in Related Biomarkers or Mechanism of Action (MOA) Recipient

Claire F. Friedman, MD
Memorial Sloan Kettering Cancer Center, United States

Amount: $40,000 for one year
Project: “The tumor immune microenvironment and response to CTLA-4 blockade in PD-1 refractory metastatic melanoma”

SITC-Bristol-Myers Squibb Cancer Immunotherapy Translational Fellowship

Benjamin Izar, MD, PhD
Dana-Farber Cancer Institute, United States

Amount: $200,000 for two years
Project: “Dissecting the role of tissue-specific anti-tumor immunity following PD-1 blockade”

SITC-EMD Serono Cancer Immunotherapy Clinical Fellowship Recipient

Eric L. Smith, MD, PhD
Memorial Sloan Kettering Cancer Center, United States

Amount: $100,000 for one year
Project: “Investigating and manipulating the interplay between the tumor microenvironment and Chimeric Antigen Receptor T cell therapy to generate durable remissions in multiple myeloma”

SITC-Genentech Cancer Immunotherapy Basic Fellowship in Related Biomarkers Recipient

Ada G. Blidner, MSc, PhD
Immunopathology Laboratory
Institute of Biology and Experimental Medicine, Argentina

Amount: $40,000 for one year
Project: “Unraveling the role of the galectin-1/glycan axis in T cell exhaustion and resistance to cancer immunotherapy”

SITC-MRA Young Investigator Award Recipient

Ping-Chih Ho, PhD
University of Lausanne, Switzerland

Amount: $225,000 for three years
Project: “Immunometabolic editing facilitates immune evasion in melanomas”

2016 NCI Immunotherapy Fellowship Recipient

Co-Sponsored by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and SITC, made possible in part by an educational grant from EMD Serono. This 1-year program allows the fellow to have exposure to multiple clinical immunotherapeutic approaches and also to key opinion leaders in the field of clinical immunotherapy.

Julius Strauss, MD
National Cancer Institute, National Institutes of Health, United States